Importantly, GLP-1 mimetics, such as Liraglutide has rescued the AD-related reduction in cortical activity and energy utilisation22, and a recently phase II clinical trial testing Exenatide has impeded PD progression25. The gene discussed is GCG; the disease is Parkinson disease.